A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Inclusion Criteria:

* Signed informed consent
* ECOG performance status of 0, 1, or 2
* Completion of treatment in a previous Genentech sponsored, Phase II cancer study with pertuzumab, either alone or with a combination agent, in which at least one dose of pertuzumab was received in the parent study
* Less than 3 months since last dose of pertuzumab on the parent study
* Use of an effective means of contraception for men or for women of childbearing potential
* Granulocyte count \>= 1500/uL
* Platelet count \>= 75,000/uL
* Hemoglobin \>= 9 g/dL (hemoglobin may be supported by transfusion or erythropoietin or other approved hematopoietic growth factors; darbepoetin \[Aranesp(R)\] is permitted)
* Serum bilirubin less than or equal to the upper limit of normal (ULN) (unless due to Gilbert's disease)
* Alkaline phosphatase, AST, and ALT \<= 2.5x ULN (\<= 5x ULN for subjects with liver metastases; no alkaline phosphatase upper limit for subjects with bone metastases)
* Serum creatinine \<= 1.5x ULN
* International normalized ratio (INR) \< 1.5 and activated partial thromboplastin time (aPTT) \< 1.5x ULN (except for subjects receiving warfarin)

Exclusion Criteria:

* Recent (within the last 3 months), current, or planned participation in a experimental drug study other than a Genentech-sponsored pertuzumab cancer study
* Any unresolved or irreversible NCI-CTC Grade 3 or 4 adverse event or clinically meaningful cardiac adverse event (any grade) that is pertuzumab-related and ongoing from the parent study
* Recent (within the last 3 months) or current treatment with HER pathway inhibitors other than pertuzumab (e.g., Herceptin(R) \[Trastuzumab\], Iressa\<TM\> \[gefitinib\], Tarceva\<TM\> \[erlotinib hydrochloride\], C225, CI1033, or TAK165) or other monoclonal antibodies
* Clinical evidence of central nervous system or brain metastases
* Ejection fraction ≤50%, as determined by ECHO (or MUGA)
* Uncontrolled hypercalcemia (\> 11.5 mg/dL)
* Recent anthracycline exposure (within the last 3 months) or cumulative exposure of \> 360 mg/m\^2 doxorubicin or equivalent (i.e., liposomal doxorubicin, \> 120 mg/m\^2 mitoxantrone, or \> 90 mg/m\^2 idarubicin)
* Ongoing corticosteroid use (except for subjects who are on stable doses of \< 20 mg of prednisone daily \[or equivalent\] or who are taking corticosteroids for reasons other than cancer)
* Other malignancies (except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, or basal or squamous cell skin cancer)
* Serious systemic disease, including active infection, uncontrolled hypertension (diastolic blood pressure \> 100 mmHg on two consecutive occasions), unstable angina, congestive heart failure, or myocardial infarction or unstable symptomatic arrhythmia requiring medication (subjects with chronic atrial arrhythmia \[i.e., atrial fibrillation\], paroxysmal supraventricular tachycardia, or controlled hypertension are eligible)
* Liver disease (including viral or other hepatitis), current alcohol abuse, or cirrhosis
* Known human immunodeficiency virus infection
* Pregnancy or lactation
* Major surgery or significant traumatic injury within 3 weeks prior to Day 1
* Inability to comply with study and follow-up procedures
* Any diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the continued use of an investigational drug or that may render the subject at high risk from treatment complications